Research Article
Midkine: A Novel Biomarker to Predict Malignancy in Patients with Nodular Thyroid Disease
Table 1
Demographic and clinical characteristics in relation to serum midkine (SMK) and nodular midkine (NMK) concentrations.
| Demographic and clinical characteristics | SMK | NMK |
| Gender | | | Female | 0.60 | 0.52 | Male | 0.63 (0.30–4.97) | 0.68 (0.35–1.73) | | 0.912 | 0.223 | Age (years) | | | <40 | 0.67 (0.37–4.97) | 0.56 (0.38–1.73) | 40–59 | 0.60 (0.30–2.77) | 0.52 (0.35–1.45) | ≥60 | 0.60 (0.40–2.03) | 0.55 (0.37–0.82) | | 0.396 | 0.298 | TSH (µIU/mL) | | | <0.4 | 0.57 (0.33–2.03) | 0.52 (0.35–0.82) | 0.4–4 | 0.63 (0.30–4.97) | 0.53 (0.35–1.73) | >4 | 0.63 (0.50–1.37) | 0.58 (0.43–0.62) | | 0.467 | 0.529 |
|
|
BMI: body mass index; TSH: thyroid stimulating hormone.
|